AVLN
Avalyn Pharma Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Avalyn Pharma Inc.
Expected move
InputsNext report
Last report
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Fund move
Fund move
No thesis.
Avalyn Pharma Inc.
25.18
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | FMRFMR | $192.1M | 13.26% | new | |
| 2 | NovoNovo | $127.8M | 8.82% | new | |
| 3 | SR One Capital ManagementSR One | $108.9M | 7.52% | new | |
| 4 | Perceptive AdvisorsPerceptive | $88.1M | 6.08% | new | |
| 5 | Suvretta Capital ManagementSuvretta | $82.4M | 5.69% | new | |
| 6 | NVP AssociatesNVP | $74.7M | 5.15% | new | |
| 7 | Wellington Management GroupWellington | $72.5M | 5.00% | new | |
| 8 | T. Rowe Price AssociatesT. Rowe Price | $57.1M | 3.94% | new | |
| 9 | Catalio Capital ManagementCatalio | $55.2M | 3.81% | new | |
| 10 | T. Rowe Price Investment ManagementT. Rowe Price | $52.8M | 3.64% | new | |
| 11 | Eventide Asset ManagementEventide | $45.3M | 3.13% | new | |
| 12 | Bellevue GroupBellevue | $44.4M | 3.07% | new | |
| 13 | BlackRockBlackRockindex-like | $32.2M | 2.22% | new | |
| 14 | Pivotal bioVenture Partners Investment AdvisorPivotal bioVenture Partners Investment Advisor | $31.8M | 2.20% | new | |
| 15 | Citadel AdvisorsCitadel | $31.6M | 2.18% | new | |
| 16 | Andera PartnersAndera Partners | $30.6M | 2.11% | new | |
| 17 | Jennison AssociatesJennison | $26.8M | 1.85% | new | |
| 18 | BraidwellBraidwell | $26.4M | 1.82% | new | |
| 19 | TPG GP ATPG GP A | $25.4M | 1.76% | new | |
| 20 | Vanguard Capital ManagementVanguardindex-like | $24.4M | 1.68% | new | |
| 21 | Deerfield ManagementDeerfield | $24.1M | 1.66% | new | |
| 22 | Rock Springs Capital ManagementRock Springs | $21.8M | 1.51% | new | |
| 23 | Geode Capital ManagementGeodeindex-like | $14.3M | 0.99% | new | |
| 24 | Soleus Capital ManagementSoleus | $13.8M | 0.95% | new | |
| 25 | Infinitum Asset ManagementInfinitum | $13.5M | 0.93% | new |
92 managers report $1.4B of Avalyn Pharma on form 13F for the quarter ended Jun 30 '26. 18 of them hold 80% of it; FMR is largest at 13.26%.
Expected move
No implied move.
No implied move.
No implied move.